70894-73-4

Usage

Uses

Used in Pharmaceutical Industry:
N-(4-bromobenzyl)-N-cyclopropylamine is used as a therapeutic agent for the treatment of drug addiction and psychiatric disorders due to its potent and selective antagonism of the dopamine D3 receptor. Its ability to modulate dopaminergic pathways offers potential benefits in managing addiction and other related conditions.
Used in Neuroprotective Applications:
N-(4-bromobenzyl)-N-cyclopropylamine is used as a neuroprotective agent to safeguard neurons from damage or degeneration. Its potential neuroprotective properties make it a candidate for the development of treatments aimed at preserving neuronal function and health.
Used in Anti-inflammatory Applications:
N-(4-bromobenzyl)-N-cyclopropylamine is used as an anti-inflammatory agent to reduce inflammation in the central nervous system. Its potential to modulate inflammatory responses may contribute to the management of neuroinflammatory conditions and promote overall brain health.
Used in Research and Development:
N-(4-bromobenzyl)-N-cyclopropylamine is used as a research compound to study the role of the dopamine D3 receptor in various physiological and pathological processes. Its selectivity for this receptor makes it a valuable tool in advancing our understanding of dopamine-related disorders and the development of targeted therapies.

InChI:InChI=1/C10H12BrN/c11-9-3-1-8(2-4-9)7-12-10-5-6-10/h1-4,10,12H,5-7H2

Upstream product

• 1122-91-4 4-bromo-benzaldehyde 
• 765-30-0 Cyclopropylamine 

Relevant academic research and scientific papers

SMALL-MOLECULE INHIBITORS FOR THE Β-CATENIN/B-CELL LYMPHOMA 9 PROTEIN?PROTEIN INTERACTION

Disclosed are inhibitors for the β-catenin/B-cell lymphoma 9 interaction. The inhibitors are selective for β-catenin/B-cell lymphoma 9 over β-catenin/ E-cadherin PPI interaction. Methods of using the disclosed compounds to treat cancer are also disclosed.

Discovery of 2-(3-(3-Carbamoylpiperidin-1-yl)phenoxy)acetic Acid Derivatives as Novel Small-Molecule Inhibitors of the β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction

The β-catenin/B-cell lymphoma 9 (BCL9) protein-protein interaction (PPI) is a potential target for the suppression of hyperactive Wnt/β-catenin signaling that is vigorously involved in cancer initiation and development. Herein, we describe the medicinal chemistry optimization of a screening hit to yield novel small-molecule inhibitors of the β-catenin/BCL9 interaction. The best compound 30 can disrupt the β-catenin/BCL9 interaction with a Ki of 3.6 μM in AlphaScreen competitive inhibition assays. Cell-based experiments revealed that 30 selectively disrupted the β-catenin/BCL9 PPI, while leaving the β-catenin/E-cadherin PPI unaffected, dose-dependently suppressed Wnt signaling transactivation, downregulated oncogenic Wnt target gene expression, and on-target selectively inhibited the growth of cancer cells harboring aberrant Wnt signaling. This compound with a new chemotype can serve as a lead compound for further optimization of inhibitors for β-catenin/BCL9 PPI.

N2-substituted alkoxy aromatic cyclo-2-aminopyrimidine derivative and application thereof

The invention provides an N2-substituted alkoxy aromatic cyclo-2-aminopyrimidine derivative and application thereof. The N2-substituted alkoxy aromatic cyclo-2-aminopyrimidine derivative comprises anoptical isomer and pharmaceutically acceptable salt thereof. Preliminary pharmacodynamic indication shows that the compound disclosed by the invention has FLT3 inhibitory activity, wherein the proliferation inhibition activity is realized on various leukemia cell strains; moreover, the derivative is effective for multiple mutations of AML, such as internal tandem repeat mutation of a near-membranestructural domain and D835 point mutation of an activated ring in a kinase structural domain and almost has no inhibition effect on c-KIT. The derivative can overcome drug resistance brought by clinical point mutation, can reduce toxic and side effects of bone marrow inhibition, and can be applied to preparation of antitumor drugs. The general structural formula of the derivative is shown in thespecification.

LINCOMYCIN DERIVATIVES AND ANTIBACTERIAL AGENTS CONTAINING THE SAME AS THE ACTIVE INGREDIENT

An objective of the present invention is to provide compounds of formula (1) or their pharmacologically acceptable salts or solvates wherein A represents aryl; R1 represents N-optionally substituted C1-6 alkyl-N-optionally substituted C1-6 alkylamino-C1-6 alkyl; R2 represents a hydrogen atom or optionally substituted C1-6 alkyl; R3 represents optionally substituted C1-6alkyl or C3-6 cycloalkyl-C1-4 alkyl; m is 1 to 3; n is 0; and p is 0 to 2. The compounds are novel lincomycin derivatives that have a potent activity against resistant Streptococcus pneumoniae, which have recently posed problems, in the treatment of infectious diseases. Further, the compounds are usable as antimicrobial agents and are useful for preventing or treating bacterial infectious diseases.

Synthesis of C-aryl-N-cyclopropylnitrones

Synthesis of C-aryl-N-cyclopropylnitrones is described. Preparations were performed either by condensation of the appropriate aldehyde with N-cyclopropyl-hydroxylamine, or oxidation of N-substituted N-cyclopropylamines with sodium tungstate/hydrogen perox